Imagine a laboratory scientist peering through a fluorescence microscope at a dish of human cells that has just been exposed to a spoonful of yogurt. The probiotic bacteria in that sample are alive and metabolically active—and that is precisely the problem. It is the kind of hidden pitfall that can make a safe product look dangerous on paper, or send a promising candidate back to the drawing board for no real reason. In modern toxicology, the 3Rs principles of reduction, replacement, and refinement have pushed the field away from animal testing and toward sophisticated cell-based alternatives. But when the product being tested is itself a living bacterial preparation, like a fermented food or a dietary probiotic, the usual sterile rules of cell culture are turned upside down. The bacteria keep multiplying during the experiment, consuming nutrients and excreting organic acids that gradually acidify the culture media. In human lymphoblastoid TK6 cells, a standard cell line for evaluating DNA damage, that acidification can produce alarming positive results in the in vitro micronucleus test—but for reasons that are completely unrelated to true genotoxicity. Researchers studying this phenomenon found that non-genotoxic organic acids, such as acetic, lactic, and formic acids, can trigger concentration-dependent false-positive chromosomal damage once the pH of the medium falls below certain thresholds. These values are not arbitrary; they align closely with the metabolic output of common probiotic organisms and help explain why live cultures have long produced inconsistent or confusing genotoxicity results. For a short 3-hour exposure, false micronucleus formation appeared at pH 6.3 or lower without metabolic activation, and at pH 6.0 or lower with metabolic activation. If exposure lasted for 24 hours, misleading positives emerged even at pH 6.7. Understanding these thresholds is essential for interpreting genotoxicity data from live probiotic products, and this article explores a study that systematically mapped these deceptive boundaries and then devised a clever antibiotic-based rescue strategy to keep the pH stable while preserving the sensitivity of the assay.
The problem is not merely a laboratory inconvenience; it is a fundamental challenge in safety assessment. Regulatory agencies and consumers both want assurance that live probiotic products are safe to eat, not just that their sterilized extracts are safe. Yet conventional genotoxicity tests are designed under strict aseptic conditions because contaminating microbes can disrupt the carefully balanced physiology of mammalian cells. In the TK6 micronucleus assay, the host cells grow in suspension, floating freely in liquid medium rather than attaching to a plate. That means technicians cannot simply wash away residual bacterial cells after treatment, as they could with adherent cell lines. Any live bacteria remaining in the culture continue to divide, release metabolic acids, and progressively lower the pH of the medium during the post-treatment recovery period. To establish a clean baseline for acid-induced effects without the complexity of living organisms, the research team first exposed TK6 cells to controlled dilutions of acetic acid, lactic acid, and formic acid—three organic acids commonly produced during bacterial fermentation. This controlled exposure was important because it mimicked the exact scenario that happens naturally when probiotic bacteria are incubated with mammalian cells. By using purified organic acids, the researchers could separate the effects of acidity from the effects of living organisms and their other metabolic products. They tested pH gradients from 6.6 down to 5.2 in 3-hour treatments, and from 6.8 down to 6.1 in continuous 24-hour treatments. Cell growth was measured using the relative increase in cell count index, comparing treated cultures with concurrent controls. The results were striking: although cell proliferation dropped sharply when the pH fell below about 6.0, significant increases in micronucleated cells appeared even in cultures where growth remained above the accepted 40% viability threshold. This demonstrated that low pH can directly induce micronucleus formation through physiological stress, independent of overt cell death. In other words, the assay can cry “genetic damage” when the real problem is simply that the cells are drowning in their own sour environment.
The biological mechanisms behind acid-induced chromosomal damage in vitro are numerous and have been explored in earlier chromosomal aberration studies. Low pH can disrupt cytoskeletal proteins, alter the dynamics of the mitotic spindle, create oxidative stress, and interfere with the enzymes that replicate and repair DNA. Any of these disruptions can lead to chromosome breaks or lagging chromosomes, which are then enclosed in small secondary nuclei visible as micronuclei. Because different mammalian cell lines show variable sensitivity to low-pH clastogenic effects, it was essential to define the precise empirical boundaries for TK6 cells, which have a stable modal chromosome count of 47 and decades of historical control data. The current study did not attempt to identify every molecular mechanism; instead, it aimed to provide practical operational limits so that laboratories can tell true genotoxins apart from pH artifacts. Notably, the fact that continuous 24-hour exposures produced false positives at pH 6.7—a milder level of acidification than the short-term threshold—suggests a cumulative or slowly developing stress response. This finding has a practical implication: checking the final pH of the culture medium after treatment may not catch transient acidification that occurred during the recovery phase. Therefore, the researchers moved to a second phase, evaluating whether antibiotics added during the recovery period could selectively stop bacterial growth without changing the response of the mammalian cells to known DNA-damaging agents. They tested penicillin-streptomycin, gentamicin sulfate, and amphotericin B in cultures previously exposed to saline controls or to validated clastogens: mitomycin C without metabolic activation and cyclophosphamide monohydrate with metabolic activation. The goal was to find the maximum non-interfering concentration of each antimicrobial, a sweet spot where bacterial contamination would be suppressed but the micronucleus assay would remain fully valid. This kind of calibration matters because the micronucleus assay is a regulatory pillar; results feed into decisions about whether a substance can proceed to clinical trials or be marketed. A false positive can be expensive and misleading, while a false negative can be dangerous.
The titration experiments yielded a set of clear, practical guidelines. Penicillin and streptomycin, used in combination, were safe up to 400 units per milliliter of penicillin and 400 micrograms per milliliter of streptomycin. At these concentrations, they did not inhibit mammalian cell proliferation, did not elevate background micronucleus frequencies, and did not reduce the positive-control response induced by mitomycin C or cyclophosphamide. Gentamicin sulfate was similarly acceptable at concentrations up to 250 micrograms per milliliter, and amphotericin B up to 20 micrograms per milliliter. But the researchers also uncovered an important caveat: antimicrobials are not biologically inert, and excessive concentrations can distort the very endpoint being measured. When recovery medium contained 800 units per milliliter of penicillin-streptomycin, or gentamicin sulfate at 500 to 1,000 micrograms per milliliter, the mitomycin C-induced micronucleus frequencies were significantly suppressed. This dampening probably resulted from secondary physiological changes—possibly alterations in cell-cycle progression, macromolecular synthesis, or gene expression profiles—rather than from any direct protection of DNA. This finding warns against the temptation to simply “throw more antibiotics at the problem.” The chosen dose must prevent bacterial growth while leaving the mammalian cell’s DNA damage response machinery untouched. The authors also acknowledged that the antimicrobial spectrum must be tailored to the specific organism being tested; a cocktail that works for lactic acid bacteria could prove useless or even harmful with a new probiotic strain. Still, the titration curves represented a much-needed methodological foundation, transforming the control of live microbial contaminants from guesswork into a reproducible, evidence-based step. These safe ranges were not arbitrary; they were selected because they maintain the delicate balance between suppressing microbial contamination and preserving the biological integrity of the host cells. This kind of dose-response characterization is exactly what regulators like to see. Instead of an all-or-nothing approach, the investigators offered a range of options that laboratories can adapt to their own quality control requirements, making the method flexible enough for a variety of product development pipelines.
The ultimate test came with a real consumer product. The researchers obtained a commercial fermented milk preparation, labeled Sample A, containing two viable strains of lactic acid-producing bacteria at more than 100 million colony-forming units per milliliter. To test the limits of their system, they deliberately administered it at an elevated concentration of 10 microliters per milliliter—five times higher than the 2 microliters per milliliter limit specified in Test Guideline 487 for conventional liquids. This aggressive dosing ensured that the culture was heavily exposed to live organisms and their metabolic products. It was a stress test designed to mimic a worst-case scenario, not a routine analysis; even under those pressure-cooker conditions, the antibiotic rescue strategy would need to keep the assay clean. In cultures left without recovery antibiotics, the results were chaotic. Bacteria overgrew the wells, final pH crashed, severe cytotoxicity appeared, and dense microbial aggregates covered the mammalian nuclei, making fluorescence scoring effectively impossible in the metabolically activated groups. This was the failure mode that had discouraged live probiotic testing for years. But in parallel cultures supplemented with penicillin-streptomycin at 100 or 400 units per milliliter, or gentamicin sulfate at 50 micrograms per milliliter, the outcome was completely different. The antibiotics kept bacterial proliferation under control, TK6 viability remained high, and final pH values stabilized at neutral levels identical to saline controls. Relative cell counts exceeded 80% in all antibiotic-supplemented groups, comfortably satisfying assay validity criteria. Acridine orange fluorescence microscopy revealed clean, unobstructed specimens with no visible bacterial crowding, allowing the technicians to score the standard 2,000 cells per group with confidence. Most importantly, the micronucleus frequencies in the live probiotic-exposed cultures were indistinguishable from negative controls and well within historical baseline ranges. Once the acidification artifact was removed, the fermented milk product showed no evidence of genotoxic activity. The contrast between the untreated and antibiotic-rescued cultures was so dramatic that it left little doubt about the source of historical false positives: not the bacteria themselves, but the acidic mess they left behind.
The broader significance of this study goes far beyond one sample of yogurt. By systematically mapping the pH thresholds that trigger false-positive micronucleus formation in TK6 cells, and by demonstrating that a calibrated post-treatment antibiotic wash can prevent environmental acidification, the researchers have provided a practical blueprint for assessing the genotoxicity of any non-sterile biological product. Fermented foods, live biotherapeutic products, dietary supplements, and microbiome-based therapies can now, in principle, be tested as intact substances rather than as sterilized extracts, which may not accurately represent the product a person actually consumes. This supports the growing regulatory commitment to animal-free safety assessment by removing a major technical barrier. The authors caution that applying this approach to novel biotherapeutic candidates will require tailoring antibiotic selection to the specific microbial species, and likely further validation for each unique formulation. But the underlying principle is robust: live bacteria do not have to be an obstacle to reliable in vitro testing if both pH and microbial growth are actively managed throughout the experiment. Perhaps the most encouraging message is that this is not a complicated or expensive solution. It relies on simple antibiotics already available in most tissue culture laboratories, and the protocol fits comfortably into standard genotoxicity workflows. The study also offers a broader lesson about false positives in genetic toxicology. Some historical reports of DNA damage from probiotic products may have been artifacts of acid stress, not true mutations. Now that the boundaries of that artifact are known, regulators and product developers can interpret existing data more skeptically and design future studies with much greater confidence. Published in the journal Genes and Environment by Fujiishi, Ohyama, and Okada (2024), this work is a model of methodical assay development—methodological advances like this are what make in vitro toxicology both more humane and more scientifically trustworthy. By understanding when cells are simply crying out in response to a sour environment, rather than at real DNA damage, the field can move forward with better tools and clearer answers.